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Mammalian corneal endothelial cells are considered to be non-proliferative due to
the arrest of cells at the G1 phase of the cell cycle. The purpose of this study was to
determine whether the down regulation of cyclin dependant kinase inhibitors (p21cip1 and
p27kip1) levels by Endothelin-1 (ET-1), would overcome the G1 phase arrest and promote
cell cycle progression and proliferation in cultured BCECs (Bovine corneal endothelial
cells). BCECs were isolated from bovine corneas and cultured in DMEM supplemented
with 10% serum. 5-Bromo 2-deoxy Uridine (BrdU) incorporation was determined in
serum starved cultures in 24-well plates as a measure of cell proliferation. Confluent
serum starved cells grown in T-25 flasks were treated with 100nM Endothelin-1 in
DMEM. The control cells were left untreated in serum free medium. Total cellular
protein was isolated using RIPA buffer and quantified according to the Peterson
modification of the Lowry method. The level of expression of p21cip1 and p27kip1 proteins
relative to β-actin was determined by western blotting technique. Immuno fluorescent
localization of p27kip1 was performed using polyclonal anti-p27kip1 and anti-p21cip1
antibodies in confluent and growing cells. An increase in cell proliferation was observed
in sub-confluent cultures with Endothelin-1 treatment. This evidence was supported by an
increase (~18%) in BrdU incorporation in response to Endothelin-1. Densitometry
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analysis of immunoblots revealed an increase in the expression of p27kip1 in confluent cell
cultures when compared to sub-confluent, dividing cells. p21cip1 was almost undetectable
in sub-confluent, actively dividing cultures. Immuno fluorescent analysis revealed that
the nuclear staining of p27kip1 was apparently decreased with ET-1 treatment. In
Conclusion, Endothelin-1 treatment resulted in decrease in p27kip1 and p21cip1 expression
in confluent cultures that was greatest at 30 hr of post incubation with Endothelin-1.
Endothelin-1 appears to promote cell proliferation. Expression of p27kip1 and p21cip1 was
greatly reduced in actively dividing BCECs. Endothelin-1 treatment down-regulated
these cyclin dependent kinase inhibitors and may promote cell cycle progression via this
mechanism.
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IN TR O DU C T IO N
Cornea:
The cornea is a dome shaped transparent tissue that covers the anterior of the
eye. It is a powerful refracting surface, providing two-thirds of the eye's focusing power.
The cornea does not contain blood vessels, as transparency is its primary function [5, 6].
The nutrients are supplied to the cornea via diffusion from the aqueous humour and to a
lesser extent from tear film. The cornea contains a large number of nerve endings, which
makes it a very sensitive tissue. The adult cornea is only about 0.5 millimeter thick and is
comprised of 5 layers namely the epithelium, Bowman's membrane, stroma, Descemet's
membrane and the endothelium [1-4].
The epithelium is a multi-cellular tissue layer (non-cornified stratified squamous
epithelium). The basal cells of the epithelium are easily regenerative and fast growing.
Bowman's membrane lies beneath the epithelium and it is a tough layer that protects the
corneal stroma from injury. It is also known as the anterior limiting membrane and is
about 8-14 µm thick. The stroma is a thick, transparent middle layer and lies between
Bowman’s membrane and Descemet’s membrane, representing about 90% of the
cornea’s thickness. It contains sparse keratocytes and a dense extracellular matrix of
regularly arranged collagen fibrils that run parallel to each other, giving the cornea its
clarity. Descemet’s membrane lies just beneath the stroma. This layer contains Type IV
and VII collagen. It serves as the modified basement membrane for the corneal
endothelium. The endothelium layer pumps salt and water from the cornea and keeps it
clear. The cells of the corneal endothelium are non-regenerative.

3

4
E ndothelium:
The corneal endothelium lies just beneath the Descemet's membrane. The
endothelium is a simple monolayer of differentiated cells located at the posterior surface
of the cornea and faces the anterior chamber of eye. The endothelium contains squamous,
hexagonal cells with a 4-6µm thickness. The endothelium is a continuous cellular layer
with fully attached membranes [7]. The physiological function of the corneal
endothelium is to allow the passive movement of solutes and nutrients from aqueous
humor to the stroma of the cornea, but at the same time the endothelium pumps salt and
water actively in the opposite direction from stroma to aqueous humor [6-9]. The corneal
endothelium plays an important role in maintaining the transparency of the cornea. The
transparency of the cornea depends critically upon its hydration. The hydration state of
the cornea results from equilibrium between two opposing forces: its passive tendency to
swell (imbibition pressure) is countered by an energy requiring process (active process)
which dehydrates the cornea [10]. The equilibrium is normally stable, but a net fluid
movement across the corneal endothelium from the anterior chamber to the stroma results
in swelling of the cornea and a loss of visual acuity. Maurice et al. [1971] first provided
results to support the capability of the endothelium to transport fluids across its surface
against a head pressure. The endothelial 'pump' requires the presence of sodium and
bicarbonate ions in the bathing medium [63]. The endothelial pump is also inhibited by
low temperature and ouabain, suggesting a key role for Na+/K+-ATPase in fluid
transport.
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E ndothelial C ells:
The corneal endothelial cells (CEC’s) are specialized, flattened, mitochondria-rich,
hexagonal cells [7]. The corneal endothelium is essential to the maintenance of normal
corneal hydration, thickness and transparency [6]. In addition to the critical importance of
this cell layer in pumping water and salts out of the cornea, it was found that corneal
endothelial cells do not divide in vivo once they undergo differentiation.
Corneal endothelial decompensation is one of the causes of blindness. Loss of
endothelial cells due to increasing age, trauma, disease, and/or dystrophy can reduce the
density of endothelial cells. Normally, adult human corneal endothelium cells (hCEC)
cease to proliferate and cell density keeps declining when people grow older. Throughout
life, endothelial cell division does not occur or occurs at a rate that is not enough to
compensate for the loss of dead cells. The major mechanism for repairing the integrity of
endothelium is by migration and/or enlargement of existing cells [64]. The cells respond
to this cell loss due to injury by migrating into a wound site, restoring partial tight
junctions, and reestablishing pump function. In humans, the corneal endothelium appears
to heal primarily by enlargement and migration, not by proliferation of the endothelial
cell layer. Study of the cell cycle reveals that hCEC in vitro stays at the G1 phase and
become non-proliferative [11].
The number of adult hCECs decreases steadily due to the combination of cell
death and the loss of proliferative activity. The endothelium is functional as long as it
maintains a cell density of 500-1000 cells per mm² [12]. The reduced density results in
functional loss of endothelium and the cornea ceases to be transparent and visual acuity is
lost (decompensation). Although the mitotic activity of hCECs in vitro is very limited,
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they still have potential proliferative capability [13]. In addition, corneal endothelial cells
exhibit intrinsic, age-related differences in relative proliferative capacity (14). With an
increase of an individual’s age, there is an increase in the number of hCECs that enter a
non-proliferative state in which they become refractive to mitogenic stimulation.
Although corneal endothelial cells have receptors for many growth factors, addition of
growth factors will not induce these cells to proliferate. This decreasing sensitivity to
mitogens appears to be mediated, at least in part, by age-dependent alterations in the
relative expression and activity of the cyclin-dependent kinase inhibitors, p27KIPl,
p16INK4A, and p21CIP1 [8].
Studies on hCEC cell cycle regulation revealed that they are arrested at the G1
phase and their characteristics include low proliferative ability, expression of G1 cyclin,
and increased expression of cyclin dependent kinase inhibitors (CKI) [11]. Cell
proliferation depends on the progression through the G1 phase of the cell cycle. The cell
cycle progression is controlled by several check points, each check point controlled by
the activity of cyclin/CDK (cyclin dependent kinase) complexes and CKIs. Even though
hCECs are non-proliferative under in vivo conditions, they do not lose proliferative
activity but they retain proliferative activity. hCECs were successively cultured under in

vitro conditions by providing growth factors to stimulate cell division [15]. The potential
of a cell to proliferate under in vitro conditions depends on the age of donor. A
significantly greater number of hCECs from younger donors responded to mitogenic
stimulation than that of older donors [17]. The age related differences in proliferative
capacity is due to the variation in the levels of CKIs. It was found that the CKI levels in
cells isolated from older donors were significantly greater than from younger donors [16].
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C ell C ycle:
The development from a single-celled zygote to an adult eukaryotic adult
organism requires many rounds of the cell cycle and thus is a vital process in eukaryotic
organisms. The cell cycle is a coordinated series of events that results in a eukaryotic cell
division. During each division, the cells complete an ordered set of events, which leads to
cell growth and division into two daughter cells. The events in this cell cycle include
accurate duplication of the genome and segregation of complete sets of replicated
chromosomes to each of the daughter cells. A typical mammalian cell in a culture divides
approximately every 24 hrs. The cell cycle contains four different phases: G1 (gap phase
1), S phase, G2 phase, and M phase. Each phase of the cell cycle is associated with
unique events. Activation of each phase is dependent on the proper progression through
the preceding phase. After the M phase where the cells divide, the daughter cells begin a
new cell cycle with the G1 phase, S phase and G2 phase which are collectively known as
interphase. Interphase occupies 23 hours of the 24-hour cell cycle. The gap phases serve
as simple time delays to allow the cells to grow and prepare for the next phase. G1 phase
is the first phase within interphase. The G1 phase of the cell cycle is the functional period
during which cells prepare for S phase. The duration of the G1 phase is variable even
among different cells of the same species, which depends on the external conditions and
signals from other cells. If the conditions are unfavorable, the cells in the G1 phase may
temporarily or permanently leave the cell cycle and enter G0, a quiescent phase or
arrested phase, to delay the progress through the G1 phase. The biosynthetic activities of
the cell that were slowed down during M phase will be resumed at a high rate in G1
phase. During this phase synthesis of various enzymes occurs that are required for S
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phase entry and DNA replication. The G1 phase ends with the start of DNA synthesis.
The S phase starts with the commencement of DNA synthesis and completes when all of
the chromosomes have been replicated. Thus during this phase, the amount of DNA in
the cell increases two fold. The cells then enter another gap phase, G2. During this phase,
the protein synthesis that occurs is mainly microtubule synthesis, which is required for
mitosis, the next phase of the cell cycle. The duration of the S and G2 phases are
characteristic of particular cell types, and usually they do not show much variation among
different species [18]. M phase involves a series of events that begin with nuclear
division, (karyokinesis) and end with cytokinesis, (cytoplasmic division). The M phase
typically requires less than an hour to complete its events. During karyokinesis the
duplicated elongated chromosomes undergo condensation and prepare for segregation.
Centrioles begin to move to opposite poles of the cell and mitotic spindle will be formed
by extending fibers arising from the centromeres of the cell. The mitotic spindle aligns
the chromosomes along the center of the cell and forms the metaphase plate. The paired
chromosomes separate at the kinetochore and move to opposite poles of the cell where
they decondense and form daughter nuclei. The cell is then divided in two by cytoplasmic
division, or cytokinesis, and cell division is complete.
C ell cycle regulation:
The cell cycling process is a highly regulated vital process and responds to the
specific needs of a certain tissue or cell type. In an adult tissue there will be a delicate
balance between cell proliferation and cell death (apoptosis). Any disruption of this
balance may lead to an uncontrolled cell cycle progression which may finally lead to
cancer [23].
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The hallmark of the cell cycle is an extremely accurate order and timing of
molecular events. Cell cycle regulation is a complex process. The transition between
phases of the cell cycle is regulated by check points. At each check point, cell cycle
events are monitored and any cellular damage is assessed. For example, the progression
of the cell cycle may stop in response to DNA damage. The loss of check point control
results in the accumulation of DNA damage, genomic instability, uncontrolled cell
proliferation and may finally lead to cancer [29]. There are two key classes of regulatory
molecules, cyclins and cyclin dependent kinases (CDKs). The cell cycle fate is
determined by CDKs [19]. CDKs are rate limiting factors for entry into the next phase of
the cell cycle. The activation of CDKs occurs through phosphorylation and association
with specific cyclins. The cyclin/CDK complexes are regulated by cyclin dependent
kinase inhibitors (CKIs).
Cyclins are proteins that play an important role in the progression of the cell
cycle. There are three different classes of cyclins: G1-S cyclins, S cyclins and M cyclins.
Cyclin-D plays an important role in G1-S transition along with cyclin E. Cyclin A
regulates DNA synthesis in S-phase and Cyclin B regulates M phase entry by forming a
complex with its respective partner CDK. Cyclins form a complex with a particular CDK,
that drives the cell cycle from one phase to next phase. The Cyclin/CDK complex
regulates G1-S transition by hyper-phosphorylating the Retinoblastoma protein (Rb).
Phosphorylation of Rb prevents it from binding to E2F transcription factor. Rb is a major
substrate for cyclin D dependant kinases such as CDK6, CDK4 and CDK2. E2F is a
transcription factor that induces the expression of S- phase genes.
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There are nine different classes of CDKs. Among them, CDK2, CDK4 and CDK6
are the most important CDKs that play an important role in G1 phase progression. The
level of CDK molecules is the same throughout the cell cycle but the activity of CDKs
varies within each phase of cell cycle [21]. The variation in CDK activity is due to the
changes in the levels of regulatory cyclins. The activity of CDKs is regulated through
phosphorylation and CKIs [24]. External signals like growth factors regulate the
proliferation of mammalian cells. A mitogenic signal induces the quiescent cells to
progress through the G1 phase and to commit to DNA replication. Once the cell enters S
phase, it can undergo mitosis even if mitogenic signals are deprived [20]. The regulators
of the G1 phase of the cell cycle determine whether a cell initiates DNA synthesis or not.
The progression of G1 to S phase is regulated by G1 phase regulators. Among the G1
phase regulators, G1 Cyclins and CDK inhibitors play an important role in regulation of
G1 phase progression. The cell cycle activation depends on the relative levels of cyclins
and CDKIs. When cyclin levels are relatively low, CKIs inhibit cell cycle progression,
whereas at high levels cyclins promote the progression of the cell cycle. D-type cyclins
play an important role to act as key molecules for growth factors to integrate external
signals into cell cycle regulation [21]. D- type cyclins interact with four different CDKs
(CDK2, 4, 5 and 6) but CDK4 and 6 are the major partners for D type cyclins. Growth
factors induce Cyclin D and Cyclin E gene expression [22, 25].
D-type cyclins then form complexes with CDK4 and CDK6, whereas E-type
cyclins form complexes with CDK2 [26]. The cyclin/CDK complexes undergo both
positive and negative regulation in the nucleus. The positive regulation occurs via
phosphorylation and dephosphorylation of different sites on the cyclin/CDK complex
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[27]. Full activation of the cyclin/CDK complex requires phosphorylation at specific
threonine residues catalyzed by CDK-activating kinase (CAK) and dephosphorylation at
specific tyrosine residues catalyzed by specific CDK phosphatases. The activated
cyclin/CDK complex phosphorylates Retinoblastoma protein (Rb). Phosphorylation
makes Rb unable to bind with E2F transcription factor which results in the release of
E2F. The phosphorylation status of Rb is maintained throughout the cell cycle by
different cyclin/CDK complexes at each phase. The E2F transcription factor induces the
transcription of genes required for S-phase entry as well as histone genes [28]. Negative
regulation occurs via CKIs by direct interactions with CDKs. CKIs inhibit the
progression of cell cycle by preventing phosphorylation of Rb.
CKIs are divided into two classes based on their structural and functional
properties: the INK4 class and the CIP/KIP class. INK4 class members inhibit the activity
of D-type cyclin dependant CDKs, whereas KIP class members inhibit the activity of
cyclin E and A dependant kinases. INK4 class includes p15INK4B (CDKN2B), p16INK4A
(CDNK2A) and p18INK4C (CDNK2C) proteins. All of the INK4 class members have
ankyrin repeats. These inhibitors inhibit the formation of cyclin D/CDK4 or cyclin
D/CDK6 complex by preventing the association of cyclin D and its partner. Kinase
inhibitor proteins (KIP) include p21CIP/WAF1 (CDKN1A) and p27KIP1 (CDKN1B). KIP
class members inhibit the formation of cyclin E, cyclin D and cyclin A dependent CDKs.
CDK inhibitors act as check points during the cell cycle and prevent the propagation and
replication of damaged DNA to daughter cells.
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p21 C IP1/W A F1 (p21):
p21 belongs to CIP/KIP family of CDK inhibitors. Xiong et al. identified p21 for
the first time in 1992 as a binding partner for cyclin D by using immuno precipitation
experiments with cyclins and CDK2 [30]. Several independent groups also identified p21
separately. p21 is localized to the nucleus and inhibits cell proliferation by inhibiting
CDKs and PCNA (proliferating cell nuclear antigen) of DNA polymerase. It was
described as a universal inhibitor of cyclin/CDK complex. p21 acts at a checkpoint in the
cell cycle at G1 and G2 phases. p21 inhibits the transition of G1/S and G2/M by
inhibiting CDKs [32]. p21 forms quaternary structure with PCNA, cyclinD1 and CDK2,
inhibiting phosphorylation of Rb and the release of E2F. p21 plays the role of an inhibitor
molecule of G1 phase by inhibiting cyclin A/E dependant CDK2 and cyclin D dependent
CDK4 complexes. A paradoxical role for p21 was observed in the regulation of cell
cycle. LaBaer, et al. found that p21 promotes the association of cyclin D and CDK4 in
mammary epithelial cells [31]. Some investigators found that the cyclin D/CDK4 or 6
complexes sequesters p21 from cyclin E/CDK2 complex and demonstrated that it results
in the activation of cyclin E/CDK2 complexes. The paradoxical functions of p21 in cell
proliferation are due to the differences in phosphorylation sites on p21 and its relative
levels in cell. The cellular context determines the role of p21 whether to promote or
inhibit cell proliferation [41].
Human p21 protein is 164 amino acids in length with 21kDa molecular weight.
The sequence of p21 is evolutionarily conserved among mammalian species. p21 shares
sequence homology with its CIP/KIP family members (p27 and p57) at their amino
terminal sequence. The amino-terminal sequence is required to inhibit the cyclin/CDK
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complexes, whereas carboxyl-terminal sequence is required to interact with PCNA, a
subunit of DNA polymerase [34]. The C-terminal domain of p21 interacts directly with
PCNA and inhibits DNA synthesis without altering DNA repairing mechanisms [33]. The
carboxyl-terminal sequence is required for nuclear localization of p21. The loss of 10
amino acid carboxyl terminal sequence results in abnormal localization of p21 in tumor
cells [70]. The association of the carboxyl-terminal sequence of p21 with MAPK
(mitogen activated protein kinase) protects the cells from apoptosis.
In quiescent cells, p21 is localized to the nucleus. Phosphorylation of p21 effects
its localization. Phosphorylation at Thr145 on p21 leads to relocalization to the cytoplasm
and results in its functional inactivation [36].
p21 expression is controlled by two major mechanisms: p53 dependent and p53
independent p21 regulation. Regulation of p21 expression also occurs at the post
transcriptional level. p53 is a tumor suppressor protein and also acts as transcription
factor for activation of its downstream genes [35]. p53 prevents the unregulated growth
of cells by stopping their growth or by inducing apoptosis when it senses any damage to
DNA. p53 induces transcription of p21 by binding to the promoter of p21. In irradiated
cells and cells treated with DNA damaging chemicals, the p21 expression was increased
in a p53 dependent pathway [37]. p21 is a downstream molecule to p53 by inducing cell
cycle arrest through p21 in response to any damage to DNA. Another tumor suppressor
protein, BRCA also requires p21 to mediate the cell cycle arrest [38].
There are a number of agents that induce p21 gene expression in the p53
independent pathway. Some of them are phorbol esters, okadaic acid, TGF-β, calcium,
butyrate and nerve growth factor. p21 promoter has six specific cis-acting elements (Sp1-
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Sp6). These agents induce different transcription factors of p21. Each transcription factor
binds to a specific cis-acting element of the p21 promoter and induces its transcription.
p21 is an inhibitor of the cell cycle in both in vivo and in vitro conditions. A paradoxical
role for p21 role was observed in regulation of cell cycle and showed that p21 promotes
cell proliferation in mouse uterine luminal epithelium [39]. Addition of exogenous p21 in
tumor cells and normal cells resulted in arrest of cell cycle at the G1 phase [40].
p27 K IP1 (p27):
p27 is also a member of the universal CDK inhibitor family, CIP/KIP. Polyak, et
al. and Toyoshima and Hunter, two independent groups, first cloned the p27 gene in 1994
[42]. They described p27 as an anti mitogenic signal. p27 is an important regulator
molecule of G1 phase progression through its inhibition of G1 cyclin dependent CDK
complexes that mediate the progression of cell cycle [51]. p27 inhibits the
phosphorylation of the cyclin/CDK complex which is required for activation of
cyclin/CDK complex and G1 phase progression. p27 levels are high in G1 phase arrested
and quiescent cells. Over expression of p27 causes the G1 phase arrest. Along with its
CDK inhibitory actions, p27 can also act as a putative tumor suppressor gene. A loss or
reduction of p27 expression was observed in several human cancers. Even the lack of a
single copy of the p27 gene gives hypersensitivity to cancer. p27 knockout mice develop
cancer in the pituitary gland [48]. p27 also acts as a regulator in cell differentiation and
apoptosis. Over expression of p27 promoted apoptosis in mammalian cells [49].
The p27 gene is located on chromosome 12p-13 [45]. All of the members of the
CIP/KIP family show great sequence homology. The p27 protein shares 42% homology
with p21 and 47% homology with p57 at its amino-terminal sequence. Amino terminal
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sequence mediates the inhibitory activity of p27, whereas carboxyl-terminal contains a
bipartite signal for nuclear localization. Crystallography studies revealed that the amino
terminal sequence of p27 interacts with the phosphorylated cyclin E/CDK2 complex
which results in conformational changes in CDK and inhibition of phosphorylation on
CDK [43].
The activity of p27 is regulated by its levels relative to cyclins as well as its subcellular localization. If the relative levels of p27 are high then p27 causes cell cycle arrest
and if the cyclins levels are high, cell cycle progression occurs. Generally p27 mRNA
levels are constant in all phases of cell cycle but p27 protein levels are under tight
translational control at each phase [50]. The levels are highest in quiescent cells and
lowest during G1 to S phase progression. In G0 phase p27 is predominantly in a
monomeric form, whereas during G1 phase p27 is associated with cyclin D and the p27
levels are significantly lower than levels of cyclin D. p27 binds preferentially to the
cyclin/CDK complex rather than to monomeric CDKs. In growing cells most of the p27
associates with cyclin D, and in growth-arrested cells as cyclin D undergoes degradation
p27 binds to cyclin A/CDK2 complex.
Transforming growth factor β (TGF-β) and contact inhibition are the two most
important mechanisms that regulate p27 expression [44]. The treatment of cells with
TGF-β and induction of contact inhibition (contact inhibition is the arrest of cell division
when cells come into contact with each other and form junctional complexes) induces the
expression p27. The p27 levels are increased in quiescent, contact inhibited and serum
deprived cells and decreased in response to mitogens. Constitutive expression of p27
results in the arrest of the cell cycle. p27 mediated cell cycle arrest can be overcome by
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inhibiting p27 expression by introducing p27 antisense oligonucleotides [46] and p27
siRNA [47] which indicates that p27 mediates the cell cycle arrest.
Post-translational modifications like phosphorylation regulate p27 by changing its
concentration, location, or association with cyclin/CDK complexes. Differential
phosphorylation of p27 determines the localization and stability of p27. Cyclin E/CDK2
phosphorylates p27 at the threonine-187 residue in late G1 phase. This is a prerequisite
for ubiquitin-mediated protein degradation. Mitogen activated protein (MAP) kinases
phosphorylate p27 at serine-10 residue. Ser-10 phosphorylation stabilizes p27 and
induces nuclear export to the cytoplasm [53].
Phopshatidylinositol-3-phosphate (PI 3)-kinase plays an important role in
regulating the function of p27 by modulating p27 transcription, protein concentration and
its subcellular location. Protein kinase B/Akt (Akt) is involved, along with PI 3-kinase, in
regulating p27 levels and its localization [54]. Activation of PI 3-kinase/Akt pathway by
a mitogen promotes cell cycle progression in quiescent cells by activating cyclin/CDK
complexes. Activated PI 3-kinase phosphorylates p27 at ser-10 residue which results in
nuclear export and inactivation of p27 [55]. Ras and c-myc are also important mediators
of p27. Over-expression of c-myc results in inactivation of p27. C-myc induces the
binding of heat labile factor with p27 and inhibits p27 interaction with cyclin E/CDK2
complex. Ras is a negative regulator of p27 and required p27 degradation [65].
p27 degradation or proteolysis occurs during the G1-S phase transition of cell
cycle. The half-life of p27 in quiescent cells is six to eight fold longer than that of
dividing cells. p27 degradation occurs via the ubiquitin-proteosome pathway [68].
Phosphorylation of threonine-187, at late G1 phase, is the signal for ubiquitination of
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p27. Cyclin E/CDK2 mediates the phosphorylation of p27 at the Thr-187 residue.
Ubiquitin protein ligase (SCF) mediates the conjugation of ubiquitin to p27. The
ubiquinated p27 then undergoes degradation in proteosome complex.
E ndothelin 1:
Endothelins are a family of three peptides designated ET-1, ET-2 and ET-3.
Yanagisawa first described endothelin in 1988 as a long lasting vasoconstrictive agent
from bovine vascular endothelial cells [56]. The endothelins are small peptides, 21 amino
acids in length that contain two intra chain disulfide bonds between cysteine residues.
All three isoforms form an unusual semi-conical structure. ET-1 shows highest sequence
and structural homology with ET-2. ET-1 differs from ET-2 by just two amino acids and
by six amino acids with ET-3. The C-terminal domain and disulfide bonds are very
important for biological activity of the endothelins and their removal leads to the loss of
biological activity of endothelin [57]. Among these three endothelins, ET-1 and ET-2
exhibit highest vasoconstrictor activity.
Yangisawa et al. also observed the expression of ET-1 mRNA in endothelial cells
when they were exposed to adrenaline, thrombin and calcium ionophores. The production
of ET-1 is also induced by several vasoactive hormones such as angiotensin II, arginine
vasopressin, cytokines, growth factors and stress. The synthesis of endothelin-1 was
observed in a variety of tissues such as blood vessels, heart, lung, pancreas, spleen,
kidney, posterior pituitary and cerebral neurons. Nitric oxide and nitro vasodilators
inhibit the synthesis of endothelin-1.
The translational products of endothelin genes are immature endothelins that are
called preproendothelins. They undergo enzymatic proteolysis to give mature
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endothelins. Each precursor molecule of the endothelin family is encoded by a separate
gene [59]. The gene that codes for preproendothelin-1 is located on human chromosome
6, whereas the gene for the precursor molecule for endothelin-3 is located on
chromosome 20. The 5’ region of preproendothelin-1 gene contains regulatory elements
such as nuclear factor 1, acute phase reactant regulatory elements and AP1. The AP1 site
is required for tissue specific transcription of the preproendothelin-1 gene.
Preproendothelin-1 mRNA gives a 212 amino acid preproendothelin-1 which undergoes
enzymatic cleavage to form mature endothelin-1. A specific endoprotease cleaves
preproendothelin-1 at Lys 52-Arg-53 and at Lys-91-Arg-92 and gives proendothelin-1
with 38 amino acids [56]. Endothelin converting enzyme (ECE) cleaves proendothelin-1
at Trp-21-Val-22 and gives the mature, biologically active endothelin-1 [56].
The actions of ET-1 are mediated through high affinity receptors. Two high
affinity receptors (ETA and ETB) have been cloned and identified for endothelins in blood
vessels, heart, adrenal glands, kidneys and brain. The human ETA receptor gene is located
on chromosome 4 and encodes a protein with 427 amino acids. The ETB receptor
consists of 442 amino acids and shares 55% sequence homology with the ETA receptor.
Both ETA and ETB have seven hydrophobic membrane-spanning domains and show
structural similarities with G-protein coupled receptors.
In addition to vasoconstrictive properties, ET-1 also acts as a potent mitogen for
many cultured cells [61]. The mitogenic responses for endothelin were observed in
smooth muscle cells, fibroblasts, cardiocytes and glomerular mesangial cells. ET-1
exerted its mitogenic response by inducing ETA receptors in mesangial cells [62].
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The binding of ET-1 to its high affinity receptors activates phospho-lipase C
(PLC). Activated PLC elevates the levels of ionositol triphosphate and induces an
increase in intracellular calcium in a biphasic manner that results in muscle contraction
and relaxation. The calcium comes from intracellular stores as well as extracellular
sources. Voltage dependent and independent calcium ion channels play an important role
in the endothelin-1 mediated mitogenic response [60]. PLC also activates protein kinase
C by increasing diacylglycerol levels. Protein kinase C activation leads to the
transcription of growth promoting genes like c-fos and c-myc [61] which are important
for cell proliferation [59].

H Y PO T H ESIS A N D PU RPOSE
ET-1 acts as a mitogen for many cell types and induces cell proliferation. The
binding of ET-1 to its receptor leads to the increased expression of growth promoting
proto-oncogenes, c-fos, c-jun and c-myc through the activation of the MAP kinase (ERK)
signal transduction pathway. It is also known that differentiated CECs are arrested at the
G1 phase of the cell cycle due to the increased levels of cyclin dependant kinase
inhibitors in the nucleus (eg. p27 and p21). The purpose of the present study was to
demonstrate the mitogenic role of ET-1 using a bovine corneal endothelial cell culture
model system. I hypothesized that the treatment of differentiated corneal endothelial cells
with ET-1 would induce cell division by decreasing p27 and p21 levels. This work has
clinical potential because any biological molecule or chemical that lowers the expression
of p27 and p21 may potentially serve as a therapeutic agent for treating injured or
dystrophic corneas. Currently the only treatment for endothelial dystrophy or endothelial
trauma is keratoplasty (corneal transplant).
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M A T E R I A LS A N D M E T H O DS
Isolation and C ulture of Bovine Corneal E ndothelial C ells:
Bovine eyes were obtained from Kirby and Poe slaughterhouse, Alvaton, KY.
Excess tissues (muscle, fat and fascia) around the globe were trimmed and the eye was
then placed cornea side up in a shallow dish lined with sterile gauze. The eye balls were
covered with sterile gauze and soaked using 2X antibiotic solution (100X stock
pen/strep/amphotericin; Invitrogen, Carlsbad, CA) for 30 min at room temperature. The
cornea was then dissected with a 1-2 mm sclera rim and transferred to a sterile eye cup
with the endothelium side up. The endothelium was incubated with Dispase (0.125g/
5mL, Roche) dissolved in EBSS (Earle’s Balanced Salt Solution) for 90 min at 37oC.
After incubation with the Dispase enzyme, endothelial cells were gently scraped off into
solution using a silicon surgical rubber spatula. Cells were then aspirated with a sterile
Pasteur pipette and transferred to a 15 mL tube containing 5mL DMEM (Dulbecco’s
Modified Eagle Medium). The cells were pelleted by centifugation at 600xg for 2 min.
The supernatant was discarded and the pellet of cells was resuspended with 5mL of
growth medium (DMEM). Cells were transferred to T-25 flasks and fed three times per
week with DMEM supplemented with 10% iron supplemented calf serum (HyClone) and
100µL gentamicin (antibiotic) and 100µL fungizone (antimycotic) for each 100mL of
complete medium. Cultures were maintained in a CO2 incubator at 37oC and 5% CO2 (fig
1). Trypsin, 0.05% dissolved in calcium free EBSS, was used to subculture cells. The
second passage cells were used for all experiments.
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F igure 1: Cultured Bovine Corneal Endothelial Cells. Isolated BCECs were cultured in
T-25 flasks at 37oC in 5% CO2. The cells were fed 3X per week with complete DMEM.
E ndothelin-1 Stock Prepa ration:
Endothelin-1 was obtained from Sigma Chemicals, St. Louis, MO. The 20µM ET1 stock was prepared in dilute acetic acid. (One drop of glacial acetic acid was added to
15mL of nano-pure water 100µL of the diluted acetic acid was then added to 10mL of
nano-pure water and filter sterilized) 1mL of dilute acid was added to 50µg of ET-1 and
25µL ET-1 aliquots were prepared and stored at -20oC.
B rdU Incorporation Studies:
BrdU (5-bromo deoxy uridine) incorporation studies were performed to
investigate whether ET-1 induces cell proliferation in BCEC cultures. BCECs were
grown in 24 well plates until they reached 60-70% confluence. Confluent cells were then
serum starved for 24 hrs to allow for depletion of growth factors provided in the serum.
The cells were then treated with 100nM ET-1 in the presence of BrdU (10ng/ml) for 24
hrs. The positive control cells were left in serum supplemented medium in the presence
of BrdU. Control cells were left untreated (serum-free) in the presence of BrdU. After 24
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hrs of incubation, the cells were washed with 1X PBS three times and prefixed with 4%
formalin for 15 min. The cells were then fixed with 4% paraformaldehyde for 15 min and
incubated in 0.2 % TritonX-100 for 10 min to permeabilize the membranes. The fixed
cells were washed with 1N HCl on ice for 15 min and 2N HCl for 10 min at room
temperature. Immediately following an acid wash, cells were placed in borate buffer for
12 min. Then cells were washed with PBS three times for 5 min per wash and incubated
with optimized anti BrdU antibody concentration (diluted in normal goat serum at
1:1000) at 4oC for 16 hr. Following additional PBS washes, cells were incubated with
horse radish peroxidase (HRP)-conjugated secondary antibody (diluted in normal goat
serum to 1:1000) at room temperature for 1 hr. After incubation and additional washes,
cells were incubated with DAB (3,3’- diamino benzidine) for 5 min to detect BrdU
positive cells. Then labeled cells were observed under an Olympus IX51 microscope and
photographed. The percentage of BrdU positive cells for the three groups of the
experiment was determined by 3 observers in a blind evaluation arrangement fashion.
Means of the three determinations were used for analysis.
Isolation of B C E C Protein:
Cells were rinsed twice with cold EBSS for 5 min and then incubated with EBSS
containing 1mM EDTA- for 5-7 min. Using a cell scraper, cells were scraped off into
EDTA solution and were pelleted by centrifugation at 600xg for 2-3 min. The supernatant
was discarded and the cells frozen at -20oC. Cold RIPA (25 mM Tris•HCl, pH 7.6, 150
mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) was added to the pellet and
the tube was kept on ice for 5 min. 1mL of RIPA buffer was used for T-75 cm2 flasks and
0.3mL of buffer for T-25 cm2 flasks. Cells were swirled occasionally on ice and samples
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were subjected to centrifugation at 600 xg for 2 min to remove cell debris. To increase
yield, the pellet was sonicated for 10 seconds with 20% amplitude. The samples were
again placed into a centrifuge and spun at 600xg. The resulting supernatant was
transferred to a new tube for further analysis.
Estimation of Protein Concentration:
Protein concentration was determined according to the Peterson modification of
the Lowry protein determination assay [66]. Samples and BSA standards (10-100µg)
were pipetted into cuvettes. Volumes of all samples and standards were brought up to
0.5mL with dH2O. 1mL of reagent A (equal volumes of copper-tartrate-carbonate
solution, 10% SDS, 0.8N NaOH and dH2O) was added to all tubes (vortexed
immediately) and left for 10 min at room temperature. Following the incubation with
reagent A, 0.5mL of reagent B (one part of Folin-Ciocalteu Phenol Reagent to 5 parts of
dH2O) was added to all tubes and incubated for 25 min. Absorbance of standards and
samples was read at 750nm wavelength. Protein concentration of samples was calculated
from the standard curve of BSA standards.
W estern Blotting:
Sample buffer was prepared by mixing 50 µL of NuPAGE Sample Buffer (2x), 30
µL D.I. water, and 20µL of reducing agent, 0.5M DTT. Sample buffer was added in a 1:1
ratio to sample and the mixture was heated for 5 min in a boiling water bath. An equal
amount of sample was loaded in each well of pre-cast 4-20% NuPAGE gels (Invitrogen)
and the proteins were separated at constant voltage (150V for 90 min). 2µL of protein
molecular weight standards were loaded in one well of the gel. After gel electrophoresis,
the gel was removed from the gel cassette and the separated proteins were transferred
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onto nitrocellulose membranes for immuno-staining. The nitrocellulose membrane and
filter papers were wetted in transfer buffer and a blot sandwich was prepared in the
following sequence: filter pad, filter paper, gel, nitro-cellulose membrane, filter paper and
filter pad. Bubbles were removed by rolling a glass rod over the sandwich. The gel holder
cassette was then closed and placed into the transfer tank filled with transfer buffer.
Proteins were transferred at a constant 75V for one hour. To detect the possible presence
of non-transferred proteins, the gel was placed into a solution of Coomasie blue. The
nitrocellulose membrane was then placed into a flat dish and incubated with 0.2% ECL
advanced blocking solution in PBS-T (Phosphate Buffer Saline with 0.5%Tween-20)
buffer overnight at 4oC. The membrane was incubated with an optimized dilution (in
blocking solution) of primary antibody for 1.5 hr at room temperature or overnight at
4oC, with shaking. The membrane was then rinsed twice followed by two, 5 min washes
in PBS-T (30-40 mL of PBS) at room temperature, with shaking. Next the membrane was
incubated with an optimized dilution of HRP-conjugated secondary antibody for 1 hr at
room temperature, with shaking, followed by another series of rinses and washes with
PBS-T. A working solution (Super Signal West Femto Maximum Sensitivity Substrate)
for detecting antigen-antibody complex was prepared by mixing equal parts of the stable
peroxide solution and luminol/enhancer solution (Invitrogen). The working solution was
applied at 0.1mL per cm² of membrane and the blot was incubated 5 min. The blot was
then removed from the working solution and an electronic image was taken with Alpha
Innotech FluorChem HD2 [San Leandro, CA]. Densitometry studies for three proteins
(actin, p21 & p27) were done using software from Alpha Innotech FluoroChem. Actin
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protein was used as loading control to normalize the target protein levels by confirming
that an equal amount of sample was loaded in each well of the gel.
Immuno-fluorescence Studies:
BCEC2 cells were grown on sterilized glass coverslips in a 12 well plate in the
presence of complete DMEM medium. When the cells reached appropriate confluence,
they were fed with serum free medium for 24 hours. The medium was then removed and
the cells washed three times with 1X PBS for 5 min. Cells were prefixed by incubating
with 4% formalin in PBS supplemented with 1mM calcium for 15 min. The cells were
then fixed with 4% paraformaldehyde in 1X PBS for 15 min and incubated in 0.2 %
TritonX-100 for 10 min to permeabilize the membranes. Fixed cultures were washed
three times with PBS for 5 min and incubated with an optimized primary antibody
concentration (diluted in normal goat serum at 1: 1000) at 4oC for 16 hrs. Following
subsequent PBS washes, cells were incubated with optimized Dy488-conjugated
secondary antibody (diluted in normal goat serum at 1:1000) at room temperature for 1
hr. The secondary antibody solution was removed and cells were washed with PBS three
times. Coverslips were mounted on microscope slides using approximately 20µL of
mounting medium (1mL of glycerol added to 3mg of anti-fade reagent, Molecular
Probes). The slides were kept in the dark for overnight (RT) and then stored at -20oC in
freezer. Localization of target proteins was observed under a Carl Zeiss epifluorescence
microscope [AxioPlan 2 Imaging].

R ESU L TS
E ffect of E ndothelin-1 on B C E C Proliferation:
ET-1 acts as a mitogen for several cell types [61]. To observe the potential
mitogenic effect of ET-1 on BCECs, we performed ET-1 treatment on sub-confluent
BCEC cultures. The BCECs grown to 60-70% confluence in T-25 flasks were treated
with 100 nM ET-1 for 24 hr. The ET-1 treated cells showed an apparent increase in cell
number, whereas the control cells did not (Fig. 2).

F igure 2: Effect of ET-1 on BCEC proliferation. Representative pictures of control and
ET-1 treated BCECs. The BCECs were grown to 60-70% confluence and serum starved
for 24 hrs. The serum starved cells were treated with 100 nM ET-1 (Panel B) and the
control cells were left untreated in serum free medium for 24 hrs (A).
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B rdU Incorporation Studies:

B
% BrdU Positive Cells

25

20

15

10

5

0

Control

10% Serum 100 nM ET-1

F igure 3: Effect of ET-1 on BCEC proliferation. A: BCECs were grown to 60-70%
confluence in 24 well plate and serum starved for 24 hrs. In presence of BrdU (10µg/ml)
the serum starved cells were then treated with ET-1 (Panel A). After 24 hrs, the cells
were fixed and incubated with primary (anti-BrdU) antibody and secondary antibody.
BrdU incorporated cells were then stained by incubating with DAB for 5 min and
counted for all three groups. B: Incubation with 100nM ET-1 for 24 hrs stimulates cell
proliferation measured as BrdU incorporation into growing BCEC cultures. ANOVA: p =
0.012.
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BrdU incorporation studies were conducted to determine whether ET-1 acts as a
mitogen for BCECs. BrdU is a well established marker for S-phase (dividing cells) of the
cell cycle, because it becomes incorporated into DNA during S-phase. To study the effect
of ET-1 on BCEC cell proliferation, BCECs were grown in 24 well plates to 60-70%
confluence and growth was inhibited by feeding with serum-free DMEM. The growth
arrested cells were then treated with ET-1 at 100 nM for 24 hrs in the presence of BrdU at
10 µM. The BrdU positive cells were counted for control cultures, serum fed cultures and
ET-1 treated cultures (figure 3A). A significant number (~18%) of BrdU positive cells
was observed in ET-1 treated cultures.
Nuclea r localization of p27:
Immuno-fluorescence studies of p27 were initially performed to confirm the
nuclear localization of p27 in BCECs. The cells were grown on cover slips in a 12-well
plate until they reached confluence and were growth inhibited. Figure 4 shows the
representative pictures of p27 staining in growth arrested BCECs. In Figure 4(B), the
positive staining for p27 confirms the nuclear localization of p27 in growth arrested cells.
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F igure 4: Localization of p27 in BCECs. BCECs were grown to confluence on # 1.5
cover slips in 12 well plates. The cells were fixed and labeled with anti-27 antibody and
DyLight conjugated secondary antibody. p27 localization was observed under Zeiss
microscope. Immuno fluorescence studies confirmed that p27 is localized to nucleus in
confluent cultures (panel B). Panel C is a DAPI picture showing nuclear staining. Panel A
is negative control (secondary antibody alone).
p21 and p27 Protein E xp ression in Confluent and Sub-confluent C ultures:
To perform the semi-quantitative analysis of the protein expression of the p21 and
p27, we prepared protein samples from confluent and growing cultures of BCECs. Figure
5 shows the level of expression of p21 in confluent and growing cells. Results of
densitometry studies are shown in Figure 5C. The expression of p21 in growing cells
was extremely low compared to that of growth arrested cells.

31

F igure 5: p21 levels in confluent cultures of BCEC. Protein samples were prepared from
confluent cultures (panel A) and growing cultures (panel B). Equal amounts of confluent
and sub-confluent protein samples were loaded onto the 4-12% acrylamide gels for
protein separation. Separated proteins were blotted onto the nitrocellulose membrane and
immuno-staining was performed. An electronic image of each blot was taken with an
AlphaInnotech FluoroChem imager and actin (loading control) and p21 levels were
measured by densitometry. The p21 levels were normalized to actin levels and compared
between confluent cells and growing cells. In panel C the normalized p21 protein levels
have been plotted against samples. Note: The values plotted in the graph are the average
of two independent experiments.

Data for p27 expression are shown in Figures 6 and 7. To confirm the specificity
of anti-p27 antibody to bovine p27, we neutralized the polyclonal anti-p27 with a
blocking peptide against which anti-p27 was raised. We transferred separated proteins
onto the nitrocellulose membrane and incubated with anti-p27 and HRP conjugated
secondary antibody (Panel A), neutralized anti-p27 and HRP conjugated secondary
antibody (Panel B) and secondary antibody alone (Panel C). The blot (Panel A) incubated
with anti-p27 alone gave a conspicuous band and three faint high molecular weight
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bands. The incubation of the immuno-blot with neutralized anti-27 resulted in a complete
loss of the band at ~ 27kD molecular weight marker. The relative expression of p27 was
similar to that of p21. p27 protein levels were higher in confluent cells than in growing
cells (fig.7). Table 1 summerizes the results of densitometry analysis of CKI levels in
growing and in growth-inhibited cells.

F igure 6: Specificity of anti-p27 for bovine p27. Panel A represents the positive control,
panel B and C represent the negative controls. Equal amounts of protein were separated
on 4-20% NuPAGE gels and separated proteins were transferred onto nitrocellulose
membrane. In panel A, the blot was immuno-stained with anti-p27 and secondary
antibody. The blot, shown in panel B, was incubated with anti-p27 neutralized with p27
blocking peptide (1:3) against which p27 antibody was raised and secondary antibody.
The blot shown in panel C was incubated with secondary antibody only.
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F igure 7: p27 levels in confluent and sub confluent cultures.p27 levels increases in
confluent cultures of BCEC. Protein samples were prepared from confluent cultures
(panel A) and growing cultures (panel B). Equal amounts of confluent and sub-confluent
protein samples were loaded onto the 4-20% acrylamide gels for protein separation.
Separated proteins were blotted onto the nitrocellulose membrane and immuno-staining
was performed. Using an AlphaInnotech FluoroChem imager, actin (loading control) and
p27 levels were measured by densitometry. The p27 levels were normalized to actin
levels and compared between confluent cells and growing cells. In panel C the
normalized p27 protein levels are plotted for each samples. Note: The values plotted in
the graph are the average of two independent experiments.

T able1: Differences in CKI levels between sub-confluent and confluent cells:

CKI

In subconfluent cells
(CKI/actin)

In confluent cells
(CKI/actin)

Fold Difference

p27

0.36

0.52

0.8X

p21

0.15

0.47

1.7X

Note: Results are the average of two independent experiments. CKI levels are normalized
with loading control, β-Actin.
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Localization of p27 in sub-confluent and confluent cultures:
Immuno-localization studies were performed to observe the differences in p27
localization between growing and confluent cells. Figure 8 shows clearly the difference
in the localization of p27. The growing cells showed cytoplasmic location of p27,
whereas the growth arrested cells showed nuclear localization of p27 (Fig.8).

F igure 8: Localization of p27 in sub-confluent and confluent cultures. BCECs were
grown on # 1.5 cover slips. Both confluent and sub-confluent cultures were fixed and p27
was labeled with anti-27 antibody and DyLight conjugated secondary antibody. p27
localization was observed and photographed using Zeiss microscope. Immunolocalization of p27 in subconfluent cells (panel A) and in confluent cells (panel B).

E ffect of E T-1 on p27 and p21 Protein L evels:
Corneal endothelial cells are arrested at the G1 phase of the cell cycle due to the
increased levels of CKIs, p21 and p27. We hypothesized that ET-1 induces cell
proliferation in BCEC cultures by decreasing CKI levels. To determine the effect of ET-1
on CKI levels we treated serum starved cells with ET-1 at 100 nM for 24 hr. Protein
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samples were then prepared from untreated and ET-1 treated cells to analyze the CKI
levels through western blotting. The densitometry studies revealed that the CKI levels
were decreased in ET-1 treated cells. Figure 9 shows a representative immuno-blot that
demonstrates the effect of ET-1 on p27 protein levels. Panel C clearly shows that the ET1 treatment decreased p27 levels by 37.3% as compared to untreated cells. Figure 10
represents the effect of ET-1 on p21 levels. The results for p21 presented in Figure 10,
panel C are also similar to that observed for p27. The densitometry studies revealed that a
decrease of ~45.6% (see Table 2) was observed for p21 in ET-1 treated cells.

F igure 9: Effect of ET-1 on p27 levels. BCECs were grown to 90% confluence in T-25
flasks and serum starved for 24 hrs. Serum starved cells were treated with 100 nM ET-1
for 24 hrs. The control cells were left untreated. Total protein was isolated from both
control (lane A) and ET-1 treated cells (B) and equal amounts of protein were loaded on a
4-20% NuPAGE gel. The separated proteins were transferred onto nitrocellulose
membrane and immuno-staining was performed. An electronic image of the blot was
taken using Alpha Innotech and densitometry analysis was performed. β-actin was used
as a loading control. The densitometry analysis revealed that the treatment with ET-1 at
100 nM concentration resulted in a decrease in p27 levels (panel C). Note: The values
plotted in the graph are the average of two independent experiments.
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F igure 10: Effect of ET-1 on p21 levels. BCECs were grown to 90% confluence in T-25
flasks and serum starved for 24 hrs. Serum starved cells were treated with 100 nM ET-1
for 24 hrs. The control cells were left untreated. Total protein was isolated from both
control (A) and ET-1 treated cells (B) and an equal amount of protein was loaded on a 420% NuPAGE gel. The separated protein was transferred to the nitrocellulose membrane
and immunostaining was performed. Using Alpha Innotech an electronic image of the
blot was taken and a densitometry analysis was performed. β-actin was used as a loading
control. Note: The values plotted in the graph (C) are the average of two independent
experiments.
T able 2: Effect of ET-1 on CKI protein levels:
CKI

In control cells
(CKI/actin)

In ET-1 treated cells
(CKI/actin)

% decrease in CKI

p27

0.21

0.12

35.3%

p21

0.62

0.32

45.6%

Note: Results are the average of two independent experiments. CKI levels are normalized
with loading control, β-Actin. The effect of ET-1 on CKI levels is represented as the
percentage decrease in CKI levels.
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E ffect of E T-1 on nuclear p27 Staining in B C E Cs:

F igure 11: Effect of ET-1 on p27 localization. BCECs were grown to confluence on #
1.5 cover slips in 12 well plates. The cells were fixed and labeled with anti-p27 antibody
and DyLight conjugated secondary antibody. Nuclear staining of p27 in control (panel A)
and ET-1 treated cells (panel C) was observed under Zeiss microscope. Panels B and D
are DAPI images of cells in panel A and panel B, respectively.
It was reported by several research teams that p27 localizes to nucleus in growth
inhibited cells and nuclear export occurs in response to mitogenic stimulation. To observe
any disappearence of p27 in the nucleus, we conducted immuno-fluorescence studies
with growth inhibited and ET-1 treated cells. Figure 11 presents representative pictures of
p27 nuclear staining in growth inhibited (panel A) and ET-1 treated cells (panel C). The
results shown in Figure 11 revealed that the nuclear staining in ET-1 treated cells was
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apparently reduced (panel C), whereas nuclear staining was highest in growth inhibited
cells.
E ffect of Incubation T ime of E T-1 on C K I Protein Levels in Confluent Samples:
Considering the potential importance of ET-1 in treatment of corneal endothelium
damage, we treated BCECs with ET-1 at 100 nM concentration and incubated for 42 hrs
to determine the time course of ET-1’s effects on CKI expression. Protein samples were
collected at every 6 hr interval (6, 12, 18, 24, 30, 36 and 42 hr) for both control and ET-1
treated cells. The western blots were performed for both p27 and p21. The densitometry
studies were performed to measure the levels of p21 and p27 at each interval of postincubation with ET-1. We calculated the percentage decrease in CKIs level at each
interval by taking control CKI standardized value as 100%. The maximum decrease for
p21 and p27 was observed at 30 hrs of post incubation with ET-1 (figs.12 and 13). In
Figure 12, panel B shows that the maximum decrease observed for p27 with ET-1
treatment was ~56% as compared to the control sample at 30 hrs post incubation,
whereas p21 showed a 57.65% decrease as compared to the control sample. The values
are the averages of two independent experiments.
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F igure 12: Effect of ET-1 on p27 levels in BCECs. Confluent BCEC were serum starved
in DMEM for 24h to induce quiescence. The serum starved cells were treated with 100
nM Endothelin-1. Control cells were left untreated in serum free DMEM. Protein samples
were isolated using RIPA buffer at 6 hour intervals for 42 hours. Protein samples were
separated on 4-20% NuPAGE gels and transferred onto a nitrocellulose membrane.
A : Immuno-staining was performed on nitrocellulose membranes using antibodies
against β-actin (loading control) and p27kip1. C= Control, E= Endothelin-1 treated,
numbers indicate the time interval (in hours) at which protein samples were isolated.
B : Band densities were measured using an AlphaInnotech Imager for actin (loading
control) band and p27. For each interval we calculated the decrease in p27 levels and
plotted it against its time interval. The maximum decrease in p27 levels in response to
ET-1 was observed at 30 hours following incubation with ET-1. Note: The values plotted
in the graph are the average of two independent experiments.
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F igure 13: Effect of ET-1 on p21 levels in BCECs. Confluent BCECs were serum
starved in DMEM for 24h to induce quiescence. The serum starved cells were treated
with 100 nM Endothelin-1. Control cells were left untreated in serum free DMEM.
Protein samples were isolated using RIPA buffer at 6 hour intervals for 42 hours. Protein
samples were separated on 4-20% polyacrylamide gels and transferred to nitrocellulose
membrane. A : Immuno-staining was performed onto a nitrocellulose membrane using
antibodies against B-actin (loading control) and p21cip1. C= Control, E= Endothelin-1
treated, numbers indicate the time interval (in hours) at which protein samples were
isolated. B: Effect of ET-1 on p21 over time. Band densities were measured using
AlphInnothech Imager software for actin (loading control) band and p21. For each
interval we calculated the decrease in p21 levels and plotted it against its time interval.
The maximum decrease in p21 levels in response to ET-1 was observed at 30 hours of
incubation with ET-1. Note: The values plotted in the graph are the average of two
independent experiments.

D ISC USSI O N
The corneal endothelium is a monolayer of cells that is essential for maintaining
the transparency of the cornea. It has been well established that the endothelial cells are
non-proliferative under in vivo conditions. Adult corneal endothelial cells cease to
proliferate. Even though the adult corneal endothelial cells are non proliferative under in

vivo conditions, they show cell proliferation under in vitro conditions when provided with
sufficient nutrients. Baum et al. successfully cultured human corneal endothelial cells in
1979 [15].
Loss of endothelial cells occurs with aging, trauma, disease, and/or dystrophy. As
the cells are non-proliferative, there is no compensation for the loss of cells. The cell
density continues to decline as people grow older. When cell density reaches its lower
threshold level, a functional decompensation occurs and the cornea ceases to be
transparent. The endothelial decompensation is one of the major causes of blindness.
Corneal endothelial cells isolated from different age groups show variability in
proliferation rate in vitro. The rate of cell proliferation decreases with the age of an
individual [14].
In this study, my main focus was to explore the mitogenic role of ET-1 in BCEC
cultures. Previously in our laboratory, we observed that the BCECs synthesize and
secrete ET-1. ET-1 also acts as a mitogenic factor for cultured cells [61]. This finding
was confirmed in BCEC through BrdU incorporation studies (see Figure 3). In this study
we observed that the BCECs showed cell proliferation in response to continuous
exposure of cells to ET-1. The 24-hr exposure of 60-70 % subconfluent (serum starved)
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cells with 100 nM ET-1 resulted in a significantly increased number of BrdU positive
cells (~18%) which indicates ET-1 acts as a mitogen for BCECs.
The balance between cell proliferation and cellular quiescence is regulated by cell
cycle regulators, cyclins and CDKs. CDKs form complexes with their partner cyclins.
The cyclin/CDK complex induces S-phase entry by phosphorylating the Rb protein. p21
and p27, two important negative modulators located in the nucleus, regulate the activity
of cyclin/CDK complexes. p21 and p27 are the members of CIP/KIP family of CKIs. The
results of present study showed that p21 and p27 protein levels increased in the nucleus
of growth (contact) inhibited BCECs. These two proteins inactivate cyclin/CDK
complexes by inhibiting phosphorylation of the cyclin/CDK complex. The inactivation of
the cyclin/CDK complex results in the G1 phase arrest of cells. The study of cell cycle
regulation in corneal endothelial cells revealed that the quiescent corneal endothelial cells
were arrested at G1 phase of the cell cycle [11]. The cells were arrested because of the
increased CKI protein levels in the nucleus (p21 and p27). The nuclear localization of
p27 was confirmed through indirect immuno fluorescence in growth arrested cells (see
Figure 4). The comparative immuno fluorescence studies on p27 between growth
inhibited and growing BCECs revealed a change in p27 localization. We observed
nuclear localization of p27 for growth arrested cells and cytoplasmic localization in
growing cells (see figure 8). The functional activity of p27 depends on its sub cellular
localization. The cytoplasmic translocation of p27 is a prerequisite for ubiquitin mediated
proteolysis. The cytoplasmic relocalization results in functional loss of p27 by poly
ubiquitination and proteolysis [68 & 71]. CKI protein levels increase in serum-starved
and contact inhibited BCECs and decrease in growing cells or in response to growth
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factors [44]. Through western blotting studies we also observed that the CKI levels are
higher in confluent, contact inhibited cells than growing, subconfluent cells (see figures 6
& 7). The p27 protein levels are 0.8 fold higher in confluent cells than in growing cells,
whereas the p21 levels of growth inhibited cells are 1.7 fold higher than that of growing
cells (see Table 1). These observations suggest that p21 may be playing an important role
in the arrest of cell cycle in BCEC.
In this study, the role that ET-1 plays in cell proliferation and regulation of CKI
(p27 and p21) levels in BCECs was investigated. My hypothesis was that ET-1 induces
cell proliferation by down regulating the expression of CKIs. ET-1 induces cell
proliferation in several cell types by the binding to ETA receptor which leads to the
expression of growth promoting proto oncogenes c-fos, c-jun and c-myc through the
activation of MAP kinase (ERK) signal transduction pathway [61]. The results presented
here reveal a mechanism through which ET-1 induces cell proliferation by down
regulating the levels of CKIs, p21 and p27. The exposure of mitogen deprived cells to
100 nM ET-1 resulted in a decrease in p21 and p27 levels (see Figures 9 & 10). The
decrease in CKI levels was specific to ET-1 treated cells and it was not observed with
untreated cells. The specificity of the ET-1 response would be further supported by the
use of an ETA antagonist, BQ123. If BQ123 blocked the decrease in CKI levels then the
effects are specific to ET-1 and its binding to its receptor (ETA). The ET-1 exposure to
the BCECs resulted in a decrease of p27 levels by 44% and p21 levels by 47.5 % (table
2). The expression of p27 in BCEC is known to be regulated by two important
mechanisms: TGF-β and contact inhibition [44]. The treatment of RCECs (rat corneal
endothelial cells) with TGF-β and induction of contact inhibition induces the expression
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of p27 [72]. The exposure of cells to ET-1 results in the loss of cell-cell contacts because
the release of cells from contact inhibition is a signal for cells to divide. Mitogenic
signals cause a rapid decrease in p27 protein levels. Phosphorylation of p27 is the
prerequisite step for its proteolytic degradation which is mediated by Cyclin E/CDK2
complex. Phosphorylated p27 translocates to the cytoplasm where they are conjugated
with ubiquitin molecules by by one of the two E3 ubiquitin protein ligases (SCF) [73].
There are four known phosphorylation sites on the p27 molecule, but Thr-187 and Ser-10
are the most important sites used for p27 degradation. The phosphorylated p27s employ
different ubiquitin E3 ligase complexes [73]. The ubiquinated p27 then undergoes
degradation in the proteosome complex [68 & 71]. E.P. Kay et al. demonstrated that
exposure of RCECs to FGF-2 (fibroblast growth factor-2) for 24 hrs induces nuclear
export of p27 to the cytoplasm [67]. The immuno fluorescence studies of p27 in mitogen
deprived BCECs showed strong nuclear p27 staining whereas ET-1 (100 nM) treated
cells showed weak positive staining for nuclear p27 (see Figure 11). Like FGF-2, the
exposure of mitogen deprived cells for 24 hr with ET-1 resulted in a strong decrease in
nuclear p27 staining which suggests that ET-1 induces the nuclear export of p27.
Considering the potential importance of ET-1 in the treatment of corneal
endothelium damage and to document the time course of the ET-1 effect on CKI protein
levels, the mitogen deprived cells were continuously exposed to 100 nM ET-1 for
different times. The cells maintained in ET-1 free DMEM showed maximum levels of
CKIs and the cells exposed to ET-1 showed a gradual decrease in CKI levels (see Figures
12 & 13). The maximum decrease for both p21 and p27 in this study was reached after 30
hours of stimulation there after the CKI levels were increased. In comparison the RCECs
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were exposed to FGF-2 led to a maximum decrease for p27 after 24 hours of exposure
[67]. The subsequent increase in CKI levels is appears to be because of the reformation of
cell-cell contacts (contact inhibition).

C O N C L USI O N
In conclusion, the results of the present study indicate ET-1 may play an
important role in repopulating the corneal endothelium when cells are lost due to injury,
disease or age. Endothelin-1 (ET-1) is mitogenic for BCECs as it stimulates the
incorporation of BrdU. The CDK inhibitors, p21 and p27 are elevated in contact inhibited
cells and may play a role in regulating cell cycle at the G1 phase point since their levels
are high in confluent cultures. ET-1 treatment resulted in decreased levels of CDK
inhibitors. ET-1 may exert its mitogenic effect by decreasing levels of CDK inhibitors
(p21 & p27) and/or by release of contact inhibition.
F u rther studies:
The results of the present study showed that Endothelin-1 has a mitogenic role for
BCEC cultures. The specificity of the ET-1 response would be further supported by the
use of an ETA antagonist, BQ123. If BQ123 blocked the decrease in CKI levels then the
effects specific to ET-1 and it’s binding to its receptor (ETA). Though our results indicate
that ET-1 down regulates p21 and p27 levels in BCECs, it is not clear how ET-1 inducing
degradation of p21 and p27. Hence further investigation is required to determine whether
ET-1 induces the inhibitor degradation through ubiquitin mediated proteolysis or not.
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